Lynne Fahey McGrath's most recent trade in Alzamend Neuro Inc was a trade of 666 Common Stock done at an average price of $0.9 . Disclosure was reported to the exchange on April 30, 2024.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Alzamend Neuro Inc | Lynne Fahey McGrath | Director | 30 Apr 2024 | 666 | 0 | - | 0.9 | 587 | Common Stock | |
| Alzamend Neuro Inc | Lynne Fahey McGrath | Director | Purchase of securities on an exchange or from another person at price $ 0.44 per share. | 22 Mar 2023 | 10,000 | 10,000 | - | 0.4 | 4,350 | Common Stock |
| Alzamend Neuro Inc | Lynne Fahey McGrath | Director | Sale of securities on an exchange or to another person at price $ 1.21 per share. | 28 Mar 2022 | 25,000 | 75,000 | - | 1.2 | 30,325 | Common Stock |
| Alzamend Neuro Inc | Lynne Fahey McGrath | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Mar 2022 | 50,000 | 0 | - | - | Restricted Stock Grant | |
| Alzamend Neuro Inc | Lynne Fahey McGrath | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Mar 2022 | 50,000 | 100,000 | - | 0 | Common Stock |